



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 811 381 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
02.05.2003 Bulletin 2003/18

(51) Int Cl.7: **A61K 31/565**, A61K 9/06,
A61K 9/70, A61K 47/10,
A61K 47/18, A61K 47/32

(21) Application number: **97108989.1**

(22) Date of filing: **04.06.1997**

(54) **A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof**

Arzneimittel zur transdermalen Verabreichung von einem Östrogen oder Progestin oder einer Mischung davon

Composition pour l'administration transdermique d'un oestrogène, d'une progestine ou d'un mélange de ceux-ci

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL SE

(30) Priority: **06.06.1996 IT MI961152**

(43) Date of publication of application:
10.12.1997 Bulletin 1997/50

(73) Proprietor: **Permaterc N.V.**
Curaçao (AN)

(72) Inventor: **Carrara, Darío**
Hurlingham (1686), Buenos Aires (AR)

(74) Representative: **Moretti, Giorgio**
Notarbartolo & Gervasi S.p.A.,
Corso di Porta Vittoria, 9
20122 Milano (IT)

(56) References cited:
EP-A- 0 285 563 **EP-A- 0 399 432**
EP-A- 0 573 133 **WO-A-90/11064**
US-A- 4 315 925 **US-A- 4 956 171**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 811 381 B1